Sign In
10 OCT, 2014 - Terumo BCT to Participate in 4th Annual Stem Cell Meeting on the Mesa
10/2/2014

Discussion to focus on connecting point-of-care cell therapies to cell therapy research and development 

LAKEWOOD, Colo., USA—October 2, 2014 —This year at the 4th Annual Stem Cell Meeting on the Mesa, Terumo BCT will discuss how its leadership of Harvest Technologies Corporation is creating a first for the regenerative medicine industry—a one-stop-shop for opportunities ranging from cell therapy research and development, to the commercialization and distribution of point-of-care cell therapies.

The Harvest Technologies business was recently incorporated into Terumo BCT's cell processing division. This alignment establishes Terumo BCT as the only company offering cell therapy solutions from manufacturing, through washing and concentration to point of care.

Terumo BCT Presentation:

 

Title:

Connecting Point of Care to Future Regenerative Medicine Therapies

Presented By:

Sven Lee

Director, Cell Processing

Terumo BCT

 Date:

Wednesday, 8 October

Time:

2 p.m.

 

About The Stem Cell Meeting on the Mesa:

The Stem Cell Meeting on the Mesa is a three-day conference organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine that brings together senior executives and top decision-makers in the regenerative medicine and advanced therapies industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first and only event of its kind dedicated solely to facilitating connections in this sector. Combined, these meetings attract nearly 800 attendees, fostering key partnerships through more than 500 one-on-one meetings while highlighting the significant clinical and commercial progress in the field over the past year.

About Terumo BCT:

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. Terumo BCT is part of the Terumo Corporation (4543 Tokyo Stock Exchange) family of companies